cancer after clear cell histology of endometrial cancer [4.9 (1.6-11)]. We found exceptionally elevated risk of second ovarian endometrioid carcinoma after endometrial cancer of the same histology or of early onset. Risk for second kidney cancer was also increased, particularly after endometrial cancer of clear cell histology. Cancer prevention strategies should focus on these cancers after endometrial cancer diagnosis.
Cancer of the corpus uteri (commonly called endometrial cancer) predominantly occurs in postmenopausal women and is related to obesity, inflammation factors and the reproductive factors such as parity and age at birth. [1] [2] [3] According to GLOBOCAN 2012, 320,000 women developed endometrial cancer in 2012 (4.8% of all cancers in women). 4 High incidence rates of endometrial cancer were found in Northern and Western Europe (12.9-15.6 per 100,000). For instance, estimated age-standardized (European standard) incidence rate in 2012 reached 16.9 per 100,000 in Germany and 19.7 per 100,000 in Sweden, indicating that endometrial cancer was the most common gynecological cancer in both countries. 4, 5 Prognosis of endometrial cancer is generally rather good, particularly in Europe as most of the patients are diagnosed at an early stage. 1 For instance, overall 5-year relative survival estimate in Germany has been slightly increasing, but stagnating recently, reaching 81% for the 2002-2006 period 1 and the 2009-2010 period, 6 while in Sweden it has been steadily high at 84% for the 2009-2012 period. 7 Consequently, favorable survival allows an opportunity for second primary cancers (SPCs) to develop. For instance, previous studies [8] [9] [10] have reported of elevated SPC risk for colorectal, small intestinnal, urinary bladder and other cancers, while decreased SPC risk for oropharyngeal and lung cancers have been reported. 8 Nevertheless, most of previous studies have limitations such as small study samples or investigations for selected SPC only. Additionally, to our knowledge, investigations on the risk of a specific SPC after endometrial cancer in two different populations have not been reported. Therefore, using the latest version of the pooled database from 12 German cancer registries 11 and the nationwide Swedish Family Cancer Database (FCD), 12 we aimed at investigating the risk of specific SPCs in women diagnosed with endometrial cancer in the two European populations, which may offer opportunities for counseling and uptake of second cancer prevention strategies.
Material and Methods

German data
Details on the pooled German database using populationbased cancer registries data were described elsewhere. 11 Briefly, data were originally collected from cancer registries covering 13 of 16 German federal states. According to some criteria closely related to data quality, such as the proportions of patients notified by death certificate only or autopsy only (although those patients were excluded from the analyses), data from 12 cancer registries during 1997-2011 were retained in the pooled German database for further analyses, covering a population of 26.7 million people (33% of the total German population). 11 According to the rules set up by the International Agency for Research on Cancer (IARC), 13 German cancer registries did not systemically provide tumors occurring at the same organ or at the contralateral organ for SPCs. Furthermore, non-melanoma skin cancers were not comprehensively collected by German cancer registries. Cancers were recorded according to the International Classification of Diseases, 10th version (ICD-10) 14 and the percentage of microscopically verified cancer diagnosis was larger than 95% in all included registries. 11 Women aged 15 years at the diagnosis of a first endometrial cancer (ICD-10 code C54) during 1997-2011 were included in the current analyses (mortality follow-up was available until the end of 2011).
Swedish data
The Swedish FCD was used for the current study; details on this database were described elsewhere. 12 Briefly, information on cancer cases relied on separate compulsory notifications from clinicians, pathologists and cytologists and, cancers were recorded according to both ICD-7 and ICD-10 codes. 15 Close to 100% of the registered primary neoplasms were histologically verified and 98% of second neoplasms were correctly verified according to a re-evaluation study of 209 multiple primary tumors. 15 For the latest version of the years 1997-2012. Since we did not directly compare German and Swedish results, we used all Swedish endometrial cancer patients diagnosed in 1997-2012, covering a source population of 9 million Swedes; however, the same criteria applied for German data were also used for Swedish data. Swedish women aged 15 years at the diagnosis of a first endometrial cancer (ICD-7 code 172 or ICD-10 code C54) during 1997-2012 were included in the current analyses (mortality followup was available until the end of 2012).
Statistical analyses
The numbers of SPCs in women diagnosed with endometrial cancer in Germany during 1997-2011 (46,929 cases) and in Sweden during 1997-2012 (18,646 cases) are presented in Table 1 . For both German and Swedish datasets, standardized incidence ratios (SIRs), calculated as the ratio of observed to expected numbers of cases, were used to assess the risk of a specific SPC in women diagnosed with endometrial cancer. The expected number of a SPC after endometrial cancer was calculated from the strata-specific first same cancer incidence rates in the Swedish and German general population, respectively, multiplied by the corresponding person-years in women with endometrial cancer. Person-years at risk were accumulated for each patient, starting at the date of diagnosis of the first endometrial cancer and terminating on the diagnosis date of a SPC, date of death, date of emigration, or end of follow-up (end of 2011 for Germany and of 2012 for Sweden), whichever came first. All SIRs for Germany and Sweden were adjusted for age (5-year bands) and calendar period (1997-2001, 2002-2006 and 2007-2011 for Germany or 2007-2012 for Sweden) and region (12 states in Germany and 4 categories in Sweden). The 95% confidence intervals (CIs) for SIRs were calculated assuming that the cases followed a Poisson distribution. Tables A1 and A2) were used for the classification of histological subtypes of endometrial cancer, i.e., adenocarcinoma [consisting of adenocarcinoma not otherwise specified (NOS), papillary, clear cell, with squamous metaplasia, mucinous, adenosquamous, endometrioid and other adenocarcinoma], carcinoma NOS, sarcoma and other specified types and others. Further analyses on histological subtypes of second ovarian cancer based on initial significant results were also conducted.
To avoid chance findings and present data more clearly, we set up rules for showing results, i.e., only cancer sites with a total number of a specific SPC 5 cases in both countries were presented in the overall tables (Tables (1 and 2) ); for tables of further stratifications, only cancer sites with at least one significant finding observed for overall SIRs (Table 2) were presented. SAS software (version 9.3, SAS Institute, Cary, NC) was used for the data analyses. Data were collected according to cancer registry laws for each German state and according to separate compulsory notifications from clinicians, pathologists and cytologists to Swedish Cancer Registry. Data collection within the German populationbased cancer registries was carried out according to state cancer registry laws and, within this project, only completely anonymous data transferred from the cancer registries were analyzed. The project was approved by the Institutional Review Boards of Heidelberg and Lund Universities.
Contribution of data from 4 of the 12 German registries started later than 1997, i.e., Lower Saxony in 2003, Schleswig-Holstein in 1999 and Bremen and RhinelandPalatinate in 1998. Previous sensitivity analyses showed risk estimates of SPCs to be very similar when these registries were excluded from the analyses. 16 We therefore included all 12 registries in all analyses in order to ensure the maximum possible sample size.
Results
Distribution of specific SPCs in endometrial cancer survivors
Overall, 46,929 and 18,646 women diagnosed with endometrial cancer at ages 15 years in Germany during 1997-2011 and in Sweden during 1997-2012, respectively, were included in the analysis. During the follow-up interval, 2,897 and 1,706 SPCs were detected among the German and Swedish patients, respectively. The distribution of specific SPCs in women with endometrial cancer is presented in Table 1 
Risk of specific SPCs in endometrial cancer survivors
The overall SIR and the further stratification by the study period are presented in Table 2 . We found elevated SIRs in both countries for kidney and ovarian cancers, i.e., in Germany SIR was 1.6 (95% CI: 1.3-1.8) for kidney cancer and . Decreased SIRs at levels ranging from 0.6 to 0.9 were found only in Germany for upper aerodigestive tract, colorectal and liver cancers and melanoma. Although breast cancer is still the leading SPC after endometrial cancer (Table 1) , the risk of second breast cancer after endometrial cancer was flat and not statistically significant in both countries, reaching 1.0 (0.9-1.0) in Germany and 1.0 (0.9-1.0) in Sweden (Table 2) . Further stratification by study period showed no significant difference in SIRs between two study periods in both countries.
The analyses were stratified by follow-up time after diagnosis of endometrial cancer (Table 3) . For ovarian cancer, we found elevated SIRs for <1 year follow-up in Germany [5.4 (4.4-6.5) for ovarian cancer and 20 (13-29) for ovarian endometrioid histology] and in Sweden [6.5 (5.5-7.7) for ovarian cancer and 5.9 (4.5-7.7) for ovarian endometrioid histology]. For kidney cancers, we found elevated SIRs for <1 year follow-up only in Germany [3.0 (2.2-3.9)]. Elevated SIRs were also found for 1-4 years follow-up in Germany for kidney cancer [1.7 (1.3-2.1)] and in Sweden for ovarian cancer [2.5 (1.5-3.9)]; after 5 years of follow-up, elevated SIR was found only in Germany for lung cancer [1.4 (1.2-1.7)]. Decreased SIRs at levels ranging from 0.2 to 0.9 were found only in Germany for some cancers by the stratification of follow-up time (Table 3) . Only cancer sites shown in Table 1 Total number included the cancer sites not presented. Only cancer sites with at least one significant finding shown in Table 2 are presented; bold type (elevated risk) and underscored type (decreased risk): 95% CIs did not include 1.00. 1 Rounding off for SIRs above 10.
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Total number included the cancer sites not presented. Table 4 . SIRs of SPCs in endometrial cancer survivors by age at diagnosis of first endometrial cancer in Germany Only cancer sites with at least one significant finding shown in Table 2 Only cancer sites with at least one significant finding shown in Table 2 are presented; bold type (elevated risk) and underscored type (decreased risk): 95% CIs did not include 1.00. 1 Rounding off for SIRs above 10.
Cancer Epidemiology
2
Total number included the cancer sites not presented.
Cancer Epidemiology
We observed a declining trend of SIRs along with increasing age at diagnosis of first endometrial cancer for second kidney and ovarian cancers in both countries (Table 4) . The risk for second ovarian cancer after early (<55 years) onset endometrial cancer in Germany was 3.3 (2.2-4.8) and in Sweden it was 9.1 (6.6-12). Risk was highest for second ovarian cancer of endometrioid histology, reaching 9.0 (4.8-15) in Germany and 7.7 (5.1-11) in Sweden. At later (55-74 years or 75 years) onset, no significant risk elevations were observed for second ovarian cancer in Germany.
Further stratifications by histology of first endometrial cancer are presented in Table 5 for Germany (Supporting Information Appendix Table A3 for Sweden due to small number). An elevated risk of second ovarian cancer was found by endometrioid 
Discussion
We found elevated risks for SPCs that are either ovarian cancer or kidney cancer in women with endometrial cancer in both populations. Elevated risk for second ovarian endometrioid carcinoma was pronounced after early (<55 years) onset endometrial cancer (9-fold elevation in Germany and 8-fold elevation in Sweden) and in women with first endometrial cancer of endometrioid histology (6-fold elevation in Germany). We found also that women with clear cell and endometrioid histopathology of endometrial cancer had an elevated risk of second kidney cancer (4.9-fold and 1.5-fold, respectively).
Mean age at diagnosis of primary endometrial cancer was similar in Germany compare to Sweden (68 vs. 69 years), which seems high for incident endometrial cancer. Nevertheless, this observation is principally consisted with the findings from our group using an early version (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) of the same German data (median age at diagnosis of endometrial cancer with 67 years) 1 and using an early version (1961-1998) of the same Swedish data (median age at diagnosis of primary endometrial cancer with 61 years). 9 Our findings of elevated risk for SPCs that are either ovarian cancer or kidney cancer in both populations are also consistent with previous studies. 9, 17, 18 To our knowledge, this is the first population-based study investigating concordant endometrioid histology for first endometrial cancer and second ovarian cancer, but not for other histopathological subtypes. 16 Epidemiologically obesity is associated with increased risks for endometrial endometrioid carcinoma. The etiology is commonly interpreted as "unopposed estrogen" hypothesis, i.e., endometrial cancer may develop as a result of the mitogenic effects of estrogens, when these are insufficiently counterbalanced by progesterone 2 ; in another words, obesity is associated with higher levels of circulating estrogens in relation to progesterone. Obesity is also associated with elevated risk of ovarian high-grade serous carcinoma (HGSC), but the etiology is not clear. Nevertheless, heritable causes could also contribute to our findings, as suggested by an early report with partly overlapping data (1958-1998) from our group, 9 but hereditary nonpolyposis colorectal carcinoma (HNPCC) may not be involved because we did not find elevated risk for second colorectal cancer that is a part of HNPCC.
Coexisting ovarian malignancy in young women with endometrial cancer is common, for instance, it has been reported that up to 22% (23 out of 103) of women with endometrial cancer have a concurrent ovarian cancer at the time of endometrial cancer diagnosis. 19 In our study, SIRs of ovarian cancers in young patient arm (Table 4 ) and <1 year arm (Table 3) were high, which might suggest the existence of synchronous ovarian cancer. However, all SPCs included in our study were real cancers occurring at different sites/histology rather than two concomitant malignancies, as mentioned in the section of materials and methods and indicated by the study from our group. 20 Because population-based cancer registries do not routinely provide precise clinical information on treatments, we did not have stratified data by the use of oophorectomy at the time of surgery for endometrial patients. Consequently, our data on survivors of endometrial cancer included both those whose ovaries had been removed and those not. Nevertheless, we emphasized that the actual SIR of second ovarian cancers for whom with ovarian preservation at primary treatment would be different. Although the actual risk of second ovarian cancer after endometrial cancer is unclear, our finding suggests caution for women considering ovarian preservation at the time of endometrial cancer surgery. Additionally, central pathological review was not performed in our study; there might be limitations of record review in pathological subtyping, e.g., the proportion of adenosquamous subtype seems higher in German cohort, compared with Swedish data (Supporting Information Appendix Tables A1 and A2) . Nevertheless, the distribution (frequency and percent) of histological subtypes of first endometrial cancer for each of 12 German cancer registries was added as Supporting Information (Appendix Table A4 ).
We found 5-fold elevated risk of second kidney cancer in women diagnosed with clear cell histopathology of endometrial cancer, compared with only 1.5-fold elevated risk of second kidney cancer in women diagnosed with endometrioid histology of endometrial cancer (Table 5) , which is novel, though the underlying mechanism is currently unknown. However, in endometrial cancer endometrioid histology was far more common than clear cell type (89 vs. 5, Table 5 ), implying that more second kidney cancer would result after endometrioid histology. It also is noteworthy that most second kidney cancers were found after the first year of follow-up, contrary to ovarian cancer for which most cases were found within the first year after the diagnosis of endometrial cancer.
Elevated risks of second ovarian and kidney cancers found after follow-up within one year might most likely be attributed to increased medical surveillance after the diagnosis of endometrial cancer, as suggested by studies from our group (treatments for patients with endometrial cancer usually involve major surgery, which (especially within first year) leads to a careful examination of the patient and diagnosis of tumors at a variety of sites). 9, 20, 21 Decreased SIRs at levels ranging from 0.6 to 0.9 for some cancers were found only in Germany for the overall and stratified results, which might be attributed to reporting practices (e.g., incomplete case ascertainment among elderly patients in Germany) and missed death data, as suggested by our overview article. 20 Although large data from population-based cancer registries have possible inaccuracy and inconsistency, epidemiologic studies can open up new thinking and basic data for further investigations. Additionally, we found similar distribution of specific SPCs in women with endometrial cancer in the two populations, suggesting common etiology for most of SPCs after endometrial cancer and similarities in the registration for those cancers in Germany and Sweden.
A major strength of our study is the first nationwide population-based investigation in two European populations of 27 and 9 million with relatively high-quality data. Another strength is the stratified analyses by histology of first endometrial cancer, particularly the concordant investigation on endometrioid histology for first endometrial cancer and second ovarian cancer. Major limitation concern was the lack of detailed clinical and/or treatment data as population-based cancer registries do not record this kind of information routinely: (i) There were no central review of tumor histology.
(ii) No detailed data on surgery details (from the primary surgical operation or even whether it was extirpative or solely diagnostic that established the diagnosis or the operation that established the SPC). For instance, there is no stratified data on survivors of endometrial cancer by the use of oophorectomy at the time of surgery for endometrial cancer. Thereby, our data on survivors of endometrial cancer included both those whose ovaries had been removed and those not. Our finding of elevated risk of second ovarian cancer warns against ovarian preservation at the time of endometrial cancer surgery. (iii) Possible misclassification of concurrent ovarian cancer and ovarian recurrence of endometrial cancer, especially for SPCs occurring within two months after diagnosis of first endometrial cancer. However, all SPCs included in our study were real cancers occurring at different sites/histology rather than two concomitant malignancies because German cancer registries commonly did not register tumors occurring at the same organ or at the contralateral organ, according to the rules set up by the IARC 13 and, the same criteria were also used for Swedish data. Actually, our findings of elevated risks found only in <1 year follow up (Table   3 ) were attributed to increased medical surveillance after onset of endometrial cancer, as suggested by studies from our group. 20 Another limitation concerns multiple testing as these kinds of studies have an inherent problem of multiple comparisons. However, we set up rules for showing results (only cancer sites with a total number of a specific SPC 5 cases in both countries are presented in the overall Tables 1 and 2 ; only cancer sites with at least one significant finding shown in Table 2 are presented in Tables (3-5) ) and considered as major findings based on significant results in both countries. In summary, to our knowledage, this is the first nationwide population-based study investigating concordant endometrioid histology for first endometrial cancer and second ovarian cancer, for which the risks were vastly elevated. Elevated risks found within the first year follow up in this study shall only be attributed to increased medical surveillance. Since our data on survivors of endometrial cancer included both those whose ovaries had been removed and those not, we emphasized that the actual risk of second ovarian cancer for whom with ovarian preservation at primary treatment would be different. Nevertheless, our data suggest caution for women considering ovarian preservation at the time of endometrial cancer surgery. Our study indicates that risk for second ovarian cancer is increased for patients with endometrial cancer, which should be discussed with the patient. We also found an elevated risk of second kidney cancer after endometrial cancer of clear cell and endometrioid histology. Our findings suggest that cancer prevention strategies should focus on second ovarian and kidney cancers after endometrial cancer diagnosis. This may help further improve longterm survival of women with endometrial cancer.
